SCHEMBL2900012

SCHEMBL2900012

COC(=O)CC(CCC1CCN(C(=O)CCCNc2ccccn2)CC1)c1ccc(OC)nc1

nearest known ligand 0.61

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 14/20 0.61
ITGAV P06756 13/20 0.61
ITGA2B P08514 6/20 0.61
ITGB5 P18084 2/20 0.42
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
F2 P00734 1/20 0.39
GRIN2B Q13224 4/20 0.37
ITGB1 P05556 1/20 0.35
ITGB6 P18564 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899066 0.94 ITGB3 (0.69) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL2905452 0.89 ITGB3 (0.60) ITGB3ITGAVITGA2BBCHEACHE
SCHEMBL2902210 0.87 ITGB3 (0.59) ITGB3ITGAVITGA2BITGB5BCHE
SCHEMBL2905930 0.84 ITGB3 (0.85) ITGB3ITGAVITGA2BBCHEACHE
SCHEMBL8345381 0.83 ITGB3 (0.57) ITGB3ITGAVITGA2BBCHEACHE
SCHEMBL3688040 0.80 ITGB3 (0.72) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL2899617 0.78 ITGB3 (0.70) ITGB3ITGAVITGA2BITGB5ITGB1
SCHEMBL12892152 0.77 GPR119 (0.48) ITGB3ITGAVITGA2BITGB5
SCHEMBL13074861 0.77 ITGB3 (0.58) ITGB3ITGAVITGA2BGRIN2BITGB1
SCHEMBL2922341 0.76 ITGB3 (1.00) ITGB3ITGAVITGA2BITGB5ITGB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2217569-A1 ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID Janssen Pharmaceutica N.V. (BE) 2010-08-18 EP claimed
US-20090124804-A1 Enantioselective process for preparing a substituted alkanoic acid JANSSEN PHARMACEUTICA NV (BE) 2009-05-14 US claimed
WO-2009058314-A1 ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-07 WO claimed
EP-2217569-B1 ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID JANSSEN PHARMACEUTICA NV (BE) 2014-04-16 EP disclosed
EP-2217569-A1 ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID Janssen Pharmaceutica N.V. (BE) 2010-08-18 EP disclosed
WO-2009058314-A1 ENANTIOSELECTIVE PROCESS FOR PREPARING A SUBSTITUTED ALKANOIC ACID JANSSEN PHARMACEUTICA, N.V. (BE) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124804-A1 Enantioselective process for preparing a substituted alkanoic acid ITGA5, ITGA1, ITGB5 ITGB3 13/4885ITGAV 8/4885ITGA2B 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.